Published in J Am Soc Nephrol on June 01, 2005
Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol (2009) 3.01
SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol (2009) 1.70
Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol (2009) 1.58
Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol (2006) 1.40
Cystatin C and albuminuria as risk factors for development of CKD stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis (2011) 1.30
Relationship between lean body mass and serum renal biomarkers in healthy dogs. J Vet Intern Med (2015) 1.26
Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.20
Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? Arterioscler Thromb Vasc Biol (2012) 1.19
Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. Nephrol Dial Transplant (2008) 1.15
Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet Intern Med (2014) 1.13
Nitric oxide synthase derangements and hypertension in kidney disease. Curr Opin Nephrol Hypertens (2012) 1.11
The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis (2010) 1.05
Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol (2011) 1.03
Simultaneous bioanalysis of L-arginine, L-citrulline, and dimethylarginines by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.00
Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol (2007) 0.97
Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol (2009) 0.96
Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol (2007) 0.95
Coronary artery calcification, ADMA, and insulin resistance in CKD patients. Clin J Am Soc Nephrol (2008) 0.93
Peripheral vascular dysfunction in chronic kidney disease. Cardiol Res Pract (2011) 0.92
Vascular damage in kidney disease: beyond hypertension. Int J Hypertens (2011) 0.92
Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. Toxins (Basel) (2016) 0.90
Progression of renal fibrosis: the underestimated role of endothelial alterations. Fibrogenesis Tissue Repair (2012) 0.88
Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol (2014) 0.87
The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC Nephrol (2013) 0.87
Asymmetric dimethylarginine and kidney disease--marker or mediator? J Am Soc Nephrol (2005) 0.86
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol (2007) 0.86
Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res (2015) 0.86
Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol (2014) 0.86
Actin cytoskeleton modulates ADMA-induced NF-kappaB nuclear translocation and ICAM-1 expression in endothelial cells. Med Sci Monit (2011) 0.85
Reduced renal function is associated with combined increases in ventricular-systolic stiffness and arterial load in patients undergoing cardiac catheterization for coronary artery disease. Heart Vessels (2010) 0.84
Screening for chronic kidney disease in HIV-infected patients. Adv Chronic Kidney Dis (2010) 0.83
Bioanalytical profile of the L-arginine/nitric oxide pathway and its evaluation by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.83
Dietary phosphate restriction ameliorates endothelial dysfunction in adenine-induced kidney disease rats. J Clin Biochem Nutr (2012) 0.83
NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease. Am J Physiol Renal Physiol (2014) 0.83
Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease. PLoS One (2015) 0.82
Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines. Diabetes Care (2009) 0.82
Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol (2011) 0.82
Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial. Wien Klin Wochenschr (2008) 0.81
Metabolomic profiling of the autosomal dominant polycystic kidney disease rat model. Clin Exp Nephrol (2011) 0.80
Vascular effects of exercise training in CKD: current evidence and pathophysiological mechanisms. Clin J Am Soc Nephrol (2014) 0.80
Role of kidney biomarkers of chronic kidney disease: An update. Saudi J Biol Sci (2014) 0.79
Plasma ADMA associates with all-cause mortality in renal transplant recipients. Amino Acids (2015) 0.79
Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability. Dis Markers (2015) 0.77
ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiography. Medicine (Baltimore) (2017) 0.77
Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine. PLoS One (2013) 0.77
Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD. J Am Soc Nephrol (2014) 0.77
Symmetric dimethylarginine as predictor of graft loss and all-cause mortality in renal transplant recipients. Transplantation (2014) 0.76
Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass. Int J Mol Sci (2014) 0.76
Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function. Lipids Health Dis (2016) 0.76
Associations between endogenous dimethylarginines and renal function in healthy children and adolescents. Int J Mol Sci (2012) 0.76
Renin-Angiotensin system inhibitors reduce serum asymmetric dimethylarginine levels and oxidative stress in normotensive patients with chronic kidney disease. Nephron Extra (2014) 0.75
Uraemic toxins and new methods to control their accumulation: game changers for the concept of dialysis adequacy. Clin Kidney J (2015) 0.75
Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis. J Proteomics Bioinform (2015) 0.75
Assessment of endothelial dysfunction: the role of symmetrical dimethylarginine and proinflammatory markers in chronic kidney disease and renal transplant recipients. Dis Markers (2013) 0.75
Dimethylarginine dimethylaminohydrolase1 is an organ-specific mediator of end organ damage in a murine model of hypertension. PLoS One (2012) 0.75
Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage. J Am Soc Nephrol (2015) 0.75
Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Nephron number in patients with primary hypertension. N Engl J Med (2003) 6.74
Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension (2012) 6.70
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet (2008) 5.23
A genome-wide perspective of genetic variation in human metabolism. Nat Genet (2009) 5.00
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet (2008) 4.67
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
The renal arterial resistance index and renal allograft survival. N Engl J Med (2003) 4.36
Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol (2009) 4.31
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Telomere length and risk of incident cancer and cancer mortality. JAMA (2010) 3.55
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 3.48
On the replication of genetic associations: timing can be everything! Am J Hum Genet (2008) 3.32
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
HaploGrep: a fast and reliable algorithm for automatic classification of mitochondrial DNA haplogroups. Hum Mutat (2010) 3.02
Heavy metal--rely on gut feelings: novel diagnostic approach to test drug compliance in patients with lanthanum intake. Nephrol Dial Transplant (2007) 2.96
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Influences on the reduction of relative telomere length over 10 years in the population-based Bruneck Study: introduction of a well-controlled high-throughput assay. Int J Epidemiol (2009) 2.87
Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One (2010) 2.84
Wegener's granulomatosis. Lancet (2006) 2.83
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int (2005) 2.78
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant (2010) 2.70
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet (2011) 2.68
Pathogenesis and management of hypertension after kidney transplantation. J Hypertens (2011) 2.66
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Essential hypertension. Lancet (2007) 2.63
Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature (2011) 2.59
Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol (2008) 2.56
Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol (2002) 2.50
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study. PLoS One (2008) 2.37
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 2.28
Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2011) 2.27
Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ (2013) 2.24
Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes (2006) 2.23
Erythropoietin regulates endothelial progenitor cells. Blood (2003) 2.18
Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation (2006) 2.18
AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation (2003) 2.15
Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol (2009) 2.13
Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol (2010) 2.13
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation (2003) 2.12
Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant (2002) 2.10
Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke. Stroke (2013) 2.07
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension (2005) 2.01
Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet (2003) 2.00
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem (2010) 1.95
Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol (2007) 1.95
Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care (2008) 1.94
Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care (2012) 1.90
ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke (2006) 1.88
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol (2003) 1.86
The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant (2009) 1.86
Loss of podocyte aPKClambda/iota causes polarity defects and nephrotic syndrome. J Am Soc Nephrol (2009) 1.86
A genome-wide association study of metabolic traits in human urine. Nat Genet (2011) 1.84
Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Crit Care Med (2014) 1.83
Nephrogenesis is induced by partial nephrectomy in the elasmobranch Leucoraja erinacea. J Am Soc Nephrol (2003) 1.83
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol (2010) 1.82
Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA study sheds new light on intergenic regions. Circ Cardiovasc Genet (2008) 1.82
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur Heart J (2006) 1.82
Nutritional status in dialysis patients: a European consensus. Nephrol Dial Transplant (2002) 1.81
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation (2004) 1.81
Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol (2010) 1.81
Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis (2009) 1.80
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation (2003) 1.79
Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis (2009) 1.78
ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res (2003) 1.78
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation (2009) 1.73
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol (2008) 1.72